SOURCE: Corporate Profile LLC

Corporate Profile LLC

April 12, 2010 12:42 ET

Corporate Profile's Features Goldman Small Cap Research and Issues Research Update on Rexahn Pharmaceuticals, Inc.

NEW YORK, NY--(Marketwire - April 12, 2010) -  Corporate Profile's newest financial website, announces an Update. Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has issued a research update on Rexahn Pharmaceuticals, Inc., (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best-in-class oncology and CNS therapeutics. See update at or

On April 13, 2010, Rexahn is slated to present at the NASDAQ Marketsite. Goldman believes that the news could be the release of very positive full-study Phase IIa depression treatment results for Serdaxin®, and or Zoraxel™ Phase IIa trial results.

In the Goldman Select Research report on the Company, analyst Rob Goldman outlines the impact of strong Serdaxin®  results.

"Strong Serdaxin® results are a precursor to the closing of a 'Big Pharma' partnership for Rexahn's Serdaxin® in the coming months which could include $500-800M in milestone and royalty payments and investments over the next 4 years. A heavily discounted back of the envelope Net Present Value calculation for the value of such a deal could be substantial to Rexahn."

To view a full summary of the report or download the report in its entirety, please visit

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces stock market research reports. The Firm produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm's internally generated stock ideas while the Opportunity product reflects sponsored research reports. While performance is tracked separately, the same coverage criteria are utilized in determining coverage of all stocks in both research formats.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap research nor it s parent is a registered investment adviser or broker-dealer. To download our research or for more information, visit

About is a website and newsletter that provides readers and subscribers fresh, original, and highly informative ideas and market commentary that they won't get anywhere else. Content is focused on what is going on in the stock market and on Wall Street, including stories about large-capitalization as well as small-cap companies, both on the long and short side. CPreports is the sister website to

About Corporate is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in the unique platform for today's hottest tips and market info.

About Rexahn Pharmaceuticals: Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN) is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS (Central Nervous System) disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin™, Serdaxin®, and Zoraxel™ -- all potential best in class therapeutics -- and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery